Trubion Hires Stromatt as Chief Medical Officer, Replacing Burge

Xconomy Seattle — 

Trubion Pharmaceuticals, the Seattle-based developer of treatments for autoimmune diseases, said today it has hired Scott Stromatt as senior vice president and chief medical officer. Stromatt previously oversaw clinical and regulatory affairs at Seattle-based Cell Therapeutics until he resigned in April. He will replace Daniel Burge, who is leaving the company in late August for “personal reasons,” the company said. Burge, 46, a veteran of Amgen and Immunex, joined Trubion in 2004.